Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Bernstein analyst William Pickering downgrades Biohaven (NYSE:BHVN) from Outperform to Market Perform and lowers the price t...
RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Sector Perform and lowers the price target from $1...
BTIG analyst Thomas Shrader maintains Biohaven (NYSE:BHVN) with a Buy and lowers the price target from $33 to $16.
William Blair analyst Myles Minter downgrades Biohaven (NYSE:BHVN) from Outperform to Market Perform.
TD Cowen analyst Tyler Van Buren maintains Biohaven (NYSE:BHVN) with a Buy and lowers the price target from $50 to $15.
Biohaven stock plunged after the FDA rejected Vyglxia for spinocerebellar ataxia, prompting major R&D cuts and a William Bl...
